scPharmaceuticals Inc. - Common Stock (SCPH) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2017 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
SCPH
Shares outstanding
53,364,241
Price per share
$5.67
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
40,958,051
Total reported value
$232,212,551
% of total 13F portfolios
0%
Share change
+2,759,037
Value change
+$31,413,797
Number of holders
108
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of scPharmaceuticals Inc. - Common Stock (SCPH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Weiss Asset Management LP 5.4% $16,339,063 2,881,669 Weiss Asset Management LP 30 Sep 2025
GLAZER CAPITAL, LLC 4.6% $6,187,050 2,474,820 Glazer Capital, LLC 02 Sep 2025
KING LUTHER CAPITAL MANAGEMENT CORP 4% -43% $11,982,841 -$8,674,586 2,128,391 -42% Luther King Capital Management Corporation 30 Sep 2025

As of 30 Sep 2025, 108 institutional investors reported holding 40,958,051 shares of scPharmaceuticals Inc. - Common Stock (SCPH). This represents 77% of the company’s total 53,364,241 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of scPharmaceuticals Inc. - Common Stock (SCPH) together control 70% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 11% 6,059,528 0% 0.82% $34,357,524
Rubric Capital Management LP 9.6% 5,101,886 +11% 0.39% $28,927,694
Weiss Asset Management LP 5.4% 2,881,669 0.25% $16,339,063
BlackRock, Inc. 4.5% 2,380,477 +7.6% 0% $13,497,304
VANGUARD GROUP INC 4.1% 2,176,970 +19% 0% $12,343,420
TUDOR INVESTMENT CORP ET AL 4% 2,150,000 0.08% $12,190,500
KING LUTHER CAPITAL MANAGEMENT CORP 4% 2,128,391 -40% 0.05% $12,067,977
HSBC HOLDINGS PLC 3.6% 1,900,042 0.01% $10,754,238
MORGAN STANLEY 3.1% 1,672,825 -22% 0% $9,484,917
GLAZER CAPITAL, LLC 2.6% 1,381,691 0.26% $7,834,000
ALPINE ASSOCIATES MANAGEMENT INC. 1.8% 961,065 0.33% $5,449,238
Newtyn Management, LLC 1.8% 940,568 0.65% $5,333,021
GEODE CAPITAL MANAGEMENT, LLC 1.7% 892,301 +19% 0% $5,060,163
Nantahala Capital Management, LLC 1.6% 861,277 -13% 0.3% $4,883,441
STATE STREET CORP 1.6% 849,279 +5.5% 0% $4,815,412
NOMURA HOLDINGS INC 1.4% 736,041 +1014% 0.02% $4,173,353
PERCEPTIVE ADVISORS LLC 1.1% 583,142 +17% 0.1% $3,306,415
ODDO BHF ASSET MANAGEMENT SAS 1.1% 575,052 0.12% $3,260,545
ROYAL BANK OF CANADA 0.94% 500,223 -0.69% 0% $2,836,000
MILLENNIUM MANAGEMENT LLC 0.88% 471,119 -13% 0% $2,671,245
Apis Capital Advisors, LLC 0.82% 440,000 -41% 0.55% $2,494,800
Yakira Capital Management, Inc. 0.82% 438,355 0.93% $2,485,473
CenterBook Partners LP 0.65% 348,596 0.1% $1,976,539
Verition Fund Management LLC 0.65% 345,572 0.01% $1,959,393
Mint Tower Capital Management B.V. 0.63% 335,000 0.24% $1,899,000

Institutional Holders of scPharmaceuticals Inc. - Common Stock (SCPH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$191,386 $5.67 0
2025 Q3 40,958,051 $232,212,551 +$31,413,797 $5.67 108
2025 Q2 38,194,973 $145,545,847 +$3,415,860 $3.81 95
2025 Q1 37,545,308 $98,742,100 -$7,793,834 $2.63 87
2024 Q4 39,775,602 $140,813,698 +$5,279,122 $3.54 84
2024 Q3 37,253,566 $169,822,911 +$42,711,040 $4.56 93
2024 Q2 27,815,340 $121,012,278 +$4,504,275 $4.35 77
2024 Q1 26,737,974 $134,225,821 -$7,692,072 $5.02 76
2023 Q4 11,752 $73,685 $6.27 1
2023 Q3 29,932,073 $213,118,251 +$9,111,654 $7.12 73
2023 Q2 28,536,920 $290,787,452 +$40,802,287 $10.19 81
2023 Q1 24,606,169 $223,185,472 +$13,263,014 $9.07 63
2022 Q4 21,410,510 $153,514,412 +$53,697,516 $7.17 59
2022 Q3 14,022,022 $91,281,927 -$10,116,153 $6.52 38
2022 Q2 15,695,145 $75,930,511 -$3,635,985 $4.82 37
2022 Q1 15,882,655 $90,121,602 -$1,157,327 $5.68 34
2021 Q4 15,935,241 $79,992,923 -$1,598,875 $5.02 29
2021 Q3 16,228,797 $107,918,705 +$1,486,681 $6.65 30
2021 Q2 16,027,547 $97,923,582 -$7,160,389 $6.11 35
2021 Q1 17,151,570 $114,056,500 +$1,444,196 $6.65 45
2020 Q4 16,309,421 $86,277,480 -$6,506,423 $5.29 45
2020 Q3 17,093,245 $127,345,487 -$2,883,968 $7.45 48
2020 Q2 17,478,187 $128,638,483 +$36,747,188 $7.36 49
2020 Q1 12,488,415 $92,413,167 +$10,166,835 $7.40 32
2019 Q4 11,077,361 $62,695,464 +$1,611,185 $5.66 26
2019 Q3 7,577,638 $44,502,550 +$1,470,862 $5.89 24
2019 Q2 7,370,123 $23,509,457 -$276,990 $3.19 27
2019 Q1 7,483,932 $22,451,653 -$1,268,811 $3.00 32
2018 Q4 7,846,388 $29,503,290 -$769,453 $3.76 31
2018 Q3 8,046,307 $47,232,256 -$121,199 $5.87 30
2018 Q2 8,090,720 $45,788,211 -$6,150,694 $5.66 36
2018 Q1 8,320,407 $103,170,760 +$6,694,157 $12.40 37
2017 Q4 7,801,672 $94,091,230 +$94,090,991 $12.09 23